Cyproterone acetate monotherapy in advanced prostatic carcinoma

Area of Science:

• Oncology
• Endocrinology

Background:

• Advanced prostate carcinoma presents significant treatment challenges.
• Hormonal therapies are a cornerstone in managing advanced prostate cancer.

Purpose of the Study:

• To evaluate the efficacy of cyproterone acetate as monotherapy for advanced prostate carcinoma.
• To assess survival and progression rates in patients treated with cyproterone acetate.

Main Methods:

• A cohort of 18 patients with advanced prostate carcinoma received cyproterone acetate monotherapy.
• Weekly dosage of 300 mg was administered.
• Progression, survival, and response rates were monitored over time.

Main Results:

• All patients experienced disease progression, with a median time to progression of 35 months.
• The median survival time was 48 months.
• Favorable partial response, stabilization, and survival rates were observed compared to alternative therapies.

Conclusions:

• Cyproterone acetate monotherapy at 300 mg weekly demonstrates encouraging survival benefits in advanced prostate carcinoma.
• The observed outcomes suggest cyproterone acetate is a valuable treatment option for this patient population.